612 related articles for article (PubMed ID: 32980422)
21. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
22. FISH patterns of ROS1, MET, and ALK with a correlation of ALK immunohistochemistry in lung cancer: a case for introducing ALK immunohistochemistry 'Equivocal' interpretation category in the Ventana anti-ALK (D5F3) CDx assay - A tertiary cancer center experience.
Singh A; Kumar R; Shetty O; Desai S; Rane S
Indian J Cancer; 2022; 59(1):18-25. PubMed ID: 33402590
[TBL] [Abstract][Full Text] [Related]
23. NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.
Chiang S; Cotzia P; Hyman DM; Drilon A; Tap WD; Zhang L; Hechtman JF; Frosina D; Jungbluth AA; Murali R; Park KJ; Soslow RA; Oliva E; Iafrate AJ; Benayed R; Ladanyi M; Antonescu CR
Am J Surg Pathol; 2018 Jun; 42(6):791-798. PubMed ID: 29553955
[TBL] [Abstract][Full Text] [Related]
24. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
[TBL] [Abstract][Full Text] [Related]
25. Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors.
Rudzinski ER; Lockwood CM; Stohr BA; Vargas SO; Sheridan R; Black JO; Rajaram V; Laetsch TW; Davis JL
Am J Surg Pathol; 2018 Jul; 42(7):927-935. PubMed ID: 29683818
[TBL] [Abstract][Full Text] [Related]
26. Rearranged anaplastic lymphoma kinase (ALK) gene in adult-onset papillary thyroid cancer amongst atomic bomb survivors.
Hamatani K; Mukai M; Takahashi K; Hayashi Y; Nakachi K; Kusunoki Y
Thyroid; 2012 Nov; 22(11):1153-9. PubMed ID: 23050789
[TBL] [Abstract][Full Text] [Related]
27. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer.
Ginestet F; Lambros L; Le Flahec G; Marcorelles P; Uguen A
Clin Lung Cancer; 2018 Sep; 19(5):e647-e653. PubMed ID: 29801706
[TBL] [Abstract][Full Text] [Related]
29. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.
Sholl LM; Sun H; Butaney M; Zhang C; Lee C; Jänne PA; Rodig SJ
Am J Surg Pathol; 2013 Sep; 37(9):1441-9. PubMed ID: 23887156
[TBL] [Abstract][Full Text] [Related]
30. Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns.
Clavé S; Rodon N; Pijuan L; Díaz O; Lorenzo M; Rocha P; Taus Á; Blanco R; Bosch-Barrera J; Reguart N; de la Torre N; Oliveras G; Espinet B; Bellosillo B; Puig X; Arriola E; Salido M
Clin Lung Cancer; 2019 Jul; 20(4):e421-e429. PubMed ID: 30898567
[TBL] [Abstract][Full Text] [Related]
31. Fluorescent In Situ Hybridization Must be Preferred to pan-TRK Immunohistochemistry to Diagnose NTRK3-rearranged Gastrointestinal Stromal Tumors (GIST).
Castillon M; Kammerer-Jacquet SF; Cariou M; Costa S; Conq G; Samaison L; Douet-Guilbert N; Marcorelles P; Doucet L; Uguen A
Appl Immunohistochem Mol Morphol; 2021 Sep; 29(8):626-634. PubMed ID: 33758144
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization.
Chu YH; Wirth LJ; Farahani AA; Nosé V; Faquin WC; Dias-Santagata D; Sadow PM
Mod Pathol; 2020 Dec; 33(12):2458-2472. PubMed ID: 32737449
[TBL] [Abstract][Full Text] [Related]
33. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.
Rogers TM; Russell PA; Wright G; Wainer Z; Pang JM; Henricksen LA; Singh S; Stanislaw S; Grille J; Roberts E; Solomon B; Fox SB
J Thorac Oncol; 2015 Apr; 10(4):611-8. PubMed ID: 25789833
[TBL] [Abstract][Full Text] [Related]
34. Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas.
Augustin J; Gabignon C; Scriva A; Menu L; Calmel C; Scatton O; Paye F; Fléjou JF; Praz F; Cervera P; Wendum D
Virchows Arch; 2020 Jul; 477(1):33-45. PubMed ID: 32447492
[TBL] [Abstract][Full Text] [Related]
35. A systematic comparison of pan-Trk immunohistochemistry assays among multiple cancer types.
Haberecker M; Töpfer A; Melega F; Moch H; Pauli C
Histopathology; 2023 Jun; 82(7):1003-1012. PubMed ID: 36759438
[TBL] [Abstract][Full Text] [Related]
36. Molecular and Cytogenetic Features of NTRK Fusions Enriched in BRAF and RET Double-Negative Papillary Thyroid Cancer.
Wu S; Liu Y; Li K; Liang Z; Zeng X
J Mol Diagn; 2023 Aug; 25(8):569-582. PubMed ID: 37236546
[TBL] [Abstract][Full Text] [Related]
37. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
[TBL] [Abstract][Full Text] [Related]
38. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE
Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630
[No Abstract] [Full Text] [Related]
39. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing.
Koehne de González A; Mansukhani MM; Fernandes H; Hsiao SJ
Cancer Genet; 2022 Apr; 262-263():47-52. PubMed ID: 35007853
[TBL] [Abstract][Full Text] [Related]
40. NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer.
Leal JL; Peters G; Szaumkessel M; Leong T; Asadi K; Rivalland G; Do H; Senko C; Mitchell PL; Quing CZ; Dobrovic A; Thapa B; John T
Lung Cancer; 2020 Aug; 146():154-159. PubMed ID: 32540558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
